Decitabine/Cedazuridine as Maintenance Therapy
A Phase Ib Study of Oral Decitabine/Cedazuridine as Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Patients With Myeloid Neoplasms
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 22 patients (estimated)
- Sponsors
- Massachusetts General Hospital
- Collaborators
- Taiho Oncology, Inc.
- Tags
- Chemotherapy, Cytidine Deaminase Inhibitor (CDAi), Hypomethylating Agents (HMA), Nucleoside Metabolic Inhibitor, Maintenance, Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1559
- NCT Identifier
- NCT04980404
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.